A large, retrospective study at a coagulation reference laboratory

American Journal of Clinical Pathology

Volumn 147, Issue 6, 2017, Pages 632-640

  Seheult, Jansen N ^c   Meyer, Michael P ^b   Bontempo, Franklin A ^a,b   Chibisov, Irina ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR TRANSFUSION MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Direct oral anticoagulants; Direct thrombin inhibitor; Factor Xa inhibitor; Low molecular weight heparin; Lupus anticoagulant; Unfractionated heparin; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; FONDAPARINUX; HEPARIN; LUPUS ANTICOAGULANT; RIVAROXABAN; THROMBIN INHIBITOR; THROMBOPLASTIN; VIPER VENOM; WARFARIN; ANTITHROMBIN;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ADOLESCENT; ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING PARAMETERS; CHILD; CONTROLLED STUDY; DABOIA RUSSELLII; DIAGNOSTIC ERROR; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; LUPUS ANTICOAGULANT ASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TISSUE THROMBOPLASTIN INHIBITION INDEX; BLOOD; BLOOD CLOTTING TEST; INFANT; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBINS; BLOOD COAGULATION TESTS; CHILD; CHILD, PRESCHOOL; FACTOR XA INHIBITORS; FEMALE; HEPARIN; HUMANS; INFANT; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDIES; WARFARIN; YOUNG ADULT;

EID: 85031667432     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1093/AJCP/AQX035     Document Type: Review

References (31)

1. Meroni PL, Chighizola CB, Rovelli F, et al. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther. 2014;16:209.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
3. Chighizola CB, Raschi E, Banzato A, et al. The challenges of lupus anticoagulants. Expert Rev Hematol. 2016;9:389-400.
4. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost. 2001;86:83-91.
5. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/ Antiphospholipid Antibodies of the ISTH. Thromb Haemost. 1995;74:1597-1603.
6. Exner T, Triplett DA, Taberner D, et al. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost. 1991;65:320-322.
7. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737-1740.
8. Keeling D, Mackie I, Moore GW, et al; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012;157:47-58.
9. Adcock DM, Gosselin R, Kitchen S, et al. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol. 2013;139:102-109.
10. Gosselin R, Hawes E, Moll S, et al. Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels. Am J Clin Pathol. 2014;141:262-267.
11. Gosselin RC, Adcock DM. The laboratory's 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost. 2016;14:886-893.
12. Gosselin RC, Adcock DM. Assessing nonvitamin K antagonist oral anticoagulants (NOACs) in the laboratory. Int J Lab Hematol. 2015;37:46-51.
13. Bonar R, Favaloro EJ, Mohammed S, et al. The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology. 2015;47:355-364.
14. Martinuzzo ME, Barrera LH, Da MA, et al. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol. 2014;36:144-150.
15. Halbmayer WM, Weigel G, Quehenberger P, et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med. 2012;50:1601-1605.
16. Kim YA, Gosselin R, Van Cott EM. The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays. Int J Lab Hematol. 2015;37:e81-e84.
17. Góralczyk T, Iwaniec T, Wypasek E, et al. False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome. Blood Coagul Fibrinolysis. 2015;26:473-475.
18. Mani H, Hesse C, Stratmann G, et al. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost. 2013;109:127-136.
19. Merriman E, Kaplan Z, Butler J, et al. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost. 2011;105:385-386.
20. Douxfils J, Chatelain C, Chatelain B, et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost. 2013;110:283-294.
21. Ortel TL. Laboratory diagnosis of the lupus anticoagulant. Curr Rheumatol Rep. 2012;14:64-70.
22. Ortel TL. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. Am J Hematol. 2012;87:S75-S81.
23. Schjetlein R, Wisloff F. An evaluation of two commercial test procedures for the detection of lupus anticoagulant. Am J Clin Pathol. 1995;103:108-111.
24. Clinical and Laboratory Standards Institute. Laboratory Testing for the Lupus Anticoagulant; Approved Guideline. CLSI document H60-A. Wayne, PA: CLSI; 2014.
25. Ratzinger F, Lang M, Belik S, et al. Lupus-anticoagulant testing at NOAC trough levels. Thromb Haemost. 2016;116:235-240.
26. Arachchillage DR, Mackie IJ, Efthymiou M, et al. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost. 2015;13:1264-1273.
27. Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol. 2016;38:505-513.
28. Parmar K, Lefkou E, Doughty H, et al. The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in individuals receiving or not receiving an oral vitamin K antagonist. Blood Coagul Fibrinolysis. 2009;20:271-275.
29. Funk DM. Coagulation assays and anticoagulant monitoring. ASH Education Program Book. 2012;2012:460-465.
30. Shi W, Krilis SA, Chong BH, et al. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med. 1990;20:231-236.
31. College of American Pathologists (CAP). Hematology Standard HEM.38002 7/28/2015 Version. Northfield, IL: CAP Press; 2015.